Table 2.
Seropositivity for CVBD according to the epidemiological variables analyzed
| Epidemiological variable |
CVBD |
|||||
|---|---|---|---|---|---|---|
|
Positive/Total (%) | ||||||
| An | Bb | Ec | Di | Li | ||
|
Age (years) |
<1 |
2/17 (11.8) |
1/15 (6.7)** |
6/15 (40)** |
0/15 (0) |
0/14 (0) |
| 1-3 |
12/369 (3.2) |
1/361 (0.3) |
7/362 (1.9) |
2/361 (0.5) |
60/370 (16.2) |
|
| 3-7 |
7/269 (2.6) |
0/261 (0) |
12/261 (4.6) |
2/262 (0.8) |
50/270 (18.5) |
|
| >7 |
7/307 (2.3) |
2/305 (0.6) |
23/307 (7.5) |
6/305 (2) |
44/327 (13.5) |
|
| Unknown |
2/14 (14.3) |
0/14 (0) |
0/14 (0) |
2/14 (14.3) |
2/14 (14.3) |
|
| |
p value |
p = 0.14 |
p = 0.001 |
p < 0.001 |
p = 0.3 |
p = 0.14 |
|
Sex |
Male |
21/531 (4) |
3/526 (0.6) |
23/528 (4.4) |
9/527 (1.7) |
94/546 (17.2) |
| Female |
9/445 (2) |
1/430 (0.2) |
25/431 (5.8) |
3/430 (0.7) |
62/449 (13.8) |
|
| |
p value |
p = 0.08 |
p = 0.16 |
p = 0.4 |
p = 0.14 |
p = 0.16 |
|
Clinical signs |
Asymptomatic |
9/433 (2.1) |
0/416 (0) |
7/417 (1.7) |
2/416 (0.5) |
19/449 (4.2) |
| Symptomatic |
19/506 (3.8) |
3/503 (0.6) |
38/505 (7.5)** |
9/504 (1.8) |
133/513 (25.9)** |
|
| Unknown |
2/37 (5.4) |
1/37 (2.7) |
3/37 (8.1) |
1/37 (2.7) |
4/33 (12.1) |
|
| |
p value |
p = 0.13 |
p = 0.11 |
p < 0.001 |
p = 0.07 |
p < 0.001 |
|
Place of abode |
Indoor |
6/360 (1.7) |
0/346 (0) |
14/346 (4) |
2/346 (0.6) |
26/354 (7.3) |
| Outdoor |
18/357 (5)* |
1/355 (0.3) |
22/355 (6.2) |
5/355 (1.4) |
86/362 (23.8)** |
|
| Mixed |
5/256 (2) |
3/252 (1.2) |
12/255 (4.7) |
5/253 (2) |
43/276 (15.6) |
|
| Unknown |
1/3 (5.2) |
0/3 (0) |
0/3 (0) |
0/3 (0) |
1/3 (5.2) |
|
| p value | p = 0.01 | p = 0.07 | p = 0.23 | p = 0.28 | p < 0.001 | |
* p < 0.05; **p < 0.001. Abbreviations: An, Anaplasma phagocytophilum/Anaplasma platys; Bb, Borrelia burgdorferi; Ec, Ehrlichia canis; Di, Dirofilaria immitis; Li, Leishmania infantum.